Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Target IC₅₀: 1 µM inhibiting lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production

Primary Target(LPS)-stimulated IL-1 and TNF-α production

Cell permeable: yes

General description

A cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC₅₀ = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor.

A cell-permeable, reversible, and ATP-competitive cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC₅₀ = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Frasch, S.C., et al. 1998. J. Biol. Chem. 273, 8389.Blanque, R., et al. 1997. Drugs Exp. Clin. Res. 23, 63.Lee, J.C., et al. 1995. Nature 372, 739.Prichett, W., et al. 1995. J. Inflamm. 45, 97.Lee, J.C., et al. 1993. Ann. N.Y. Acad. Sci. 696, 149.

Packaging

5 mg in Plastic ampoule

Warning

Toxicity: Irritant (B)